Question special
Lead Moderator

Some evidence of greater major CVD and ASCVD risk reductions in Non-Caucasians, and in North America and Asia/Pacific regions. Any data on why this might be? lower statin dose? higher LDL-C levels?
Also few women enrolled - any considerations regarding efficacy or safety in women?